Scarica l'app Stockscreener
303.15
0.45%
1.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$301.79
Aprire:
$304.28
Volume 24 ore:
1.54M
Relative Volume:
1.83
Capitalizzazione di mercato:
$21.02B
Reddito:
$2.20B
Utile/perdita netta:
$402.20M
Rapporto P/E:
54.52
EPS:
5.56
Flusso di cassa netto:
$280.80M
1 W Prestazione:
-0.49%
1M Prestazione:
-7.43%
6M Prestazione:
+13.72%
1 anno Prestazione:
+52.10%
Intervallo 1D:
$300.59
$305.51
Intervallo di 1 settimana:
$299.47
$310.18
Portata 52W:
$173.00
$329.33
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
303.15 | 21.02B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
132.99 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
101.30 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
375.56 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.34 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.83 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Truist bullish on diabetes companies citing potential market growth - MSN
Insulet’s SWOT analysis: patch pump leader’s stock poised for growth By Investing.com - Investing.com South Africa
Insulet’s SWOT analysis: patch pump leader’s stock poised for growth - Investing.com
Analyst Predicts Strong Growth for Insulet (PODD) with Buy Ratin - GuruFocus
Insider Sell: Dan Manea Sells 1,300 Shares of Insulet Corp (PODD) - GuruFocus
Insulet, EyePoint & NanoDx receive $2M in tax incentives to create life sciences jobs - Worcester Business Journal
Insulet (PODD) Rated 'Buy' by Truist Securities; Price Target Set at $365 | PODD Stock News - GuruFocus
(PODD) Investment Report - news.stocktradersdaily.com
Truist initiates Insulet stock with buy rating on diabetes pump potential - Investing.com Nigeria
Truist Initiates Insulet at Buy With $365 Price Target - MarketScreener
Truist Securities Starts Insulet Corporation (PODD) at Buy - StreetInsider
Insulet’s SWOT analysis: pump maker’s stock rides wave of growth By Investing.com - Investing.com South Africa
Insulet’s SWOT analysis: pump maker’s stock rides wave of growth - Investing.com
Here's Why You Should Retain PODD Stock in Your Portfolio Now - MSN
Insulet Boosts Its Diabetes Device Via Comical Campaign -- And A Comic Book 06/12/2025 - MediaPost
Marvel’s latest superhero: Insulet’s comic book star with type 1 diabetes - Medical Marketing and Media
Insulet, Marvel collab to unveil comic book hero with type 1 diabetes - MassDevice
Possible Bearish Signals With Insulet Insiders Disposing Stock - simplywall.st
Insulet Director Cashes In on Stock Sale! - TipRanks
Insider Sell: Luciana Borio Sells Shares of Insulet Corp (PODD) - GuruFocus
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice
Insulet at Goldman Sachs Conference: Strategic Growth and Leadership Transition - Investing.com Nigeria
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - MarketScreener
Transcript : Insulet Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - MarketScreener
Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - marketscreener.com
Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration N - GuruFocus
Insulet announces Omnipod 5 App for iPhone is compatible with Dexcom G7 CGM - TipRanks
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire
Insulet To Present At Goldman Sachs Global Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption - Yahoo Finance
Insulet Corporation (PODD) Announces Credit Agreement Refinancin - GuruFocus
Insulet Corporation (PODD) Announces Credit Agreement Refinancing and Convertible Notes Redemption - GuruFocus
Insulet Issues Redemption Notice for Convertible Notes - TipRanks
Insulet enters eighth amendment to credit agreementSEC filing - MarketScreener
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
3 Medical Technology Stocks Outperforming in 2025 - MarketBeat
Raindrop Injects Personality Into Omnipod 5’s Diabetes Campaign - Little Black Book | LBBOnline
Omnipod 5 Helps Make Diabetes a Smaller Part of Life In New Work From Raindrop - citybiz
TD Cowen Raises Insulet (PODD) Price Target, Maintains Buy Rating - Insider Monkey
TD Cowen raises Insulet stock price target to $379 after strong Q1 - Investing.com Nigeria
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks - Yahoo Finance
Goldman Sachs Initiates Coverage of Insulet (PODD) with Buy Rating - MSN
TD Cowen raises Insulet stock price target to $379 after strong Q1 By Investing.com - Investing.com South Africa
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Insulet Corporation (PODD) PT Raised to $379 at TD Cowen After a Stellar 1Q - StreetInsider
TD Cowen Boosts Insulet (PODD) Price Target Following Strong Quarter | PODD Stock News - GuruFocus
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insulet Corporation Azioni (PODD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Singh Prem | SVP, Global Operations |
Jun 13 '25 |
Sale |
300.05 |
2,327 |
698,216 |
4,143 |
| Manea Dan | SVP, Chief HR Officer |
Jun 13 '25 |
Sale |
300.05 |
1,300 |
390,065 |
9,090 |
1.04%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):